Robust Q1; well-poised for further acceleration
03/05/21 -"Astra kicked-off 2021 on a promising note, from both a sales and profitability perspective. Besides a healthy (though somewhat slower) performance for the lynchpin oncology portfolio, the strong ..."
Pages
64
Language
English
Published on
03/05/21
You may also be interested by these reports :
23/10/25
Lonza’s strong Q3 commentary reaffirmed its commitment to meeting the 2025 guidance, boosting investor sentiment. While operational figures were not ...
22/10/25
Ipsen’s Q3 sales surpassed expectations, showing robust growth across all segments. Consequently, the 2025 guidance has been revised upwards. The ...
20/10/25
“Only when the tide goes out do you discover who’s been swimming naked.” This famous line from Warren Buffett fits well for the ...
17/10/25
The markets were jubilant with Virbac’s Q3 25 beat and a guidance upgrade, especially because the investors, in September 2025, doubted the firm’s ...